Kevin James Filipski

This inventor holds 19 USPTO granted patents and 14 published patent applications, plus 8 CIPO patents and 5 EPO patents. Top assignees: Pfizer Corporation, Other. Active years: 2006-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kevin James Filipski. Retrieved from https://idiyas.com/inventor/kevin-james-filipski

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 14)

% Patents Active = 52.6

CIPO Patents = 8 (Patent Applications = 5)

EPO Patents = 5 (Patent Applications = 13)

Average Co-Inventor Count = 7.9

ph-index = 2

Forward Citations = 63(Granted Patents)

Location History:

Canton, MI (US) (2006 - 2008)
Ivoryton, CT (US) (2013 - 2014)
Reading, MA (US) (2014 - 2023)

Company Filing History:

18 out of 4,488

Pfizer Corporation

patents

1 out of 834,513

Other

patents

Years Active: 2006-2026

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12715863 - 5-(thiophen-2-yl)-1 H-tetrazole derivative as BCKDK inhibitors useful for treating various diseases (2026-08-25),

2. 12466803 - BCKDK inhibitors and/or degraders (2025-11-11),

3. 11542270 - BCKDK inhibitors (2023-01-03),

4. 11471458 - Diacylglycerol acyl transferase 2 inhibitor (2022-10-18),

5. 11065249 - Diacylglycerol acyl transferase 2 inhibitor (2021-07-20),

6. 11059833 - BCKDK inhibitors (2021-07-13),

7. 9452999 - Glucagon receptor modulators (2016-09-27),

8. 9394285 - Indole and indazole compounds that activate AMPK (2016-07-19),

9. 9139538 - Quinolinyl glucagon receptor modulators (2015-09-22),

10. 9073871 - Glucagon receptor modulators (2015-07-07),

11. 9056834 - Glucagon receptor modulators (2015-06-16),

12. 8933104 - Glucagon receptor modulators (2015-01-13),

13. 8927577 - Quinolinyl glucagon receptor modulators (2015-01-06),

14. 8889730 - Indole and indazole compounds that activate AMPK (2014-11-18),

15. 8859591 - Glucagon receptor modulators (2014-10-14),

Title: Kevin James Filipski: Innovator in Pharmaceutical Chemistry

Introduction

Kevin James Filipski is a notable inventor based in Reading, MA (US), recognized for his contributions to pharmaceutical chemistry. With a total of 19 patents, he has made significant strides in developing compounds that target critical health issues.

Latest Patents

Filipski's latest patents include innovative compounds such as BCKDK inhibitors and/or degraders. These compounds are described as having the potential to serve as branched-chain alpha keto acid dehydrogenase kinase inhibitors and/or degraders. Their applications extend to treating various conditions, including diabetes, kidney disease, NASH, and heart failure. Additionally, he has developed BCKDK inhibitors, which are also aimed at treating diabetes, NASH, and heart failure through their pharmaceutical compositions.

Career Highlights

Throughout his career, Filipski has worked with prominent organizations, including Pfizer Corporation. His work has focused on creating effective pharmaceutical solutions that address significant health challenges.

Collaborations

Filipski has collaborated with esteemed colleagues such as Meihua Mike Tu and Mary Theresa Didiuk, contributing to the advancement of pharmaceutical research and development.

Conclusion

Kevin James Filipski's innovative work in pharmaceutical chemistry has led to the development of critical compounds that hold promise for treating various health conditions. His contributions continue to impact the field positively.

Profile summary based on public USPTO records.